Phase Ib basket expansion trial and alternative-schedule dose-escalation study of ATR inhibitor elimusertib in advanced solid tumors with DNA damage response defects

已完结 10 由 126 发布于 2025/7/4 11:06:55

DOI:10.1158/2159-8290.cd-24-1500
作者：Timothy A. Yap, David S.P. Tan, Anastasios Stathis, Geoffrey I. Shapiro, Satoru Iwasa, Markus Joerger, Jingsong Zhang, Ruth Plummer, Michael B. Sawyer, Daniel S.W. Tan, Vincent Castonguay, Nashat Y. G
文献类型：期刊论文
补充材料：只需要正文

American Association for Cancer Research (AACR)

Abstract：In this Phase Ib basket expansion trial and alternative-schedule dose-escalation study, we evaluated the ATR inhibitor elimusertib at 40 mg twice daily (3 days on/4 days off) in 143 patients

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库A Robust Infrared and Visible Image Registration Method for Dual-Sensor UAV System